Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | MIF | P14174 | 4/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528384 | 1.00 | CA2 (0.46) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL8917799 | 0.85 | CA2 (0.41) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL28924707 | 0.83 | CA2 (0.44) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL15786354 | 0.83 | CA2 (0.44) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL25961260 | 0.83 | CA2 (0.44) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL1859536 | 0.83 | CTDSP1 (0.45) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL10314728 | 0.83 | CTDSP1 (0.45) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL10314726 | 0.83 | CTDSP1 (0.45) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL17038984 | 0.81 | CA2 (0.47) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL17038983 | 0.81 | CA2 (0.47) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013080036-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-7504432-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | CA2 1629/4885TMEM97 367/4885SIGMAR1 142/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | CA2 2104/4885TMEM97 278/4885SIGMAR1 163/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | CA2 1676/4885TMEM97 340/4885SIGMAR1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.